These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 7169836)

  • 61. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Pharmacopeia and preparations for cutaneous application].
    Esnault F; Etchegaray JP; Mallard C
    Ann Dermatol Venereol; 2007 Mar; 134(3 Pt 2):2S40-5. PubMed ID: 17563714
    [No Abstract]   [Full Text] [Related]  

  • 63. Ethical implications of pediatric drug research policy initiatives.
    Twomey JG
    IRB; 2000; 22(2):5-10. PubMed ID: 11883466
    [No Abstract]   [Full Text] [Related]  

  • 64. Linking a policy on nonformulary drugs to the FDA's therapeutic-potential classification system.
    Poirier TI; Vorbach M; Bache T
    Am J Hosp Pharm; 1994 Sep; 51(18):2277-8. PubMed ID: 7801989
    [No Abstract]   [Full Text] [Related]  

  • 65. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles.
    Rajaram L; Roy SK; Skerjanec A
    Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918
    [TBL] [Abstract][Full Text] [Related]  

  • 66. FDA's Kessler: a prescription for change. Interview by Marlene Z. Bloom.
    Kessler DA
    Am Pharm; 1991 Dec; NS31(12):34-7. PubMed ID: 1763774
    [No Abstract]   [Full Text] [Related]  

  • 67. Monitoring of clinical investigations; availability of guideline--FDA. Notice.
    Fed Regist; 1988 Feb; 53(31):4723-4. PubMed ID: 10285639
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharma's year of trouble and strife.
    Frantz S
    Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339
    [No Abstract]   [Full Text] [Related]  

  • 69. Ethical problems arise over clinical trials on new drugs.
    Hosp Ethics; 1992; 8(5):12-3. PubMed ID: 10120132
    [No Abstract]   [Full Text] [Related]  

  • 70. [FDA's new drug approval system].
    Ishii A
    Gan To Kagaku Ryoho; 1995 Aug; 22(9):1146-51. PubMed ID: 7661565
    [No Abstract]   [Full Text] [Related]  

  • 71. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Implications of FDA's proposal to include foreign marketing experience in the over-the-counter drug review process.
    Pinco RG
    Food Drug Law J; 1998; 53(1):105-22. PubMed ID: 11795327
    [No Abstract]   [Full Text] [Related]  

  • 73. Not enough warning. GAO report finds FDA's medical device monitoring lacking.
    Hensley S
    Mod Healthc; 1997 Mar; 27(10):102, 104. PubMed ID: 10165267
    [No Abstract]   [Full Text] [Related]  

  • 74. FDA cracks down on labeling, initiates trial result reporting.
    Osborne R; Waltz E
    Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742
    [No Abstract]   [Full Text] [Related]  

  • 75. Drug metabolites in safety testing.
    Baillie TA; Cayen MN; Fouda H; Gerson RJ; Green JD; Grossman SJ; Klunk LJ; LeBlanc B; Perkins DG; Shipley LA
    Toxicol Appl Pharmacol; 2002 Aug; 182(3):188-96. PubMed ID: 12229863
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The FDA's regulation of pharmaceutical communications in the context of managed care: a suggested approach.
    Kuhlik BN
    Food Drug Law J; 1995; 50(1):23-48. PubMed ID: 10342984
    [No Abstract]   [Full Text] [Related]  

  • 77. The intensified drug inspection program: procedures and results.
    Clevenger WL
    Bull Parenter Drug Assoc; 1969; 23(6):263-8. PubMed ID: 5355888
    [No Abstract]   [Full Text] [Related]  

  • 78. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 79. The regulation of clinical research.
    Schiffrin MJ
    J Clin Pharmacol; 1977; 17(11-12):686-90. PubMed ID: 925188
    [No Abstract]   [Full Text] [Related]  

  • 80. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy?
    Lovell MC
    Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.